http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-076601-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eebe74c1fee5cf462287d54ba4aa4010 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2613944636ab2fdf3f83ef2d4b304f0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| filingDate | 2010-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-076601-A1 |
| titleOfInvention | PYRIMIDINS AS THERAPEUTIC AGENTS |
| abstract | A compound of any of the Formulas ((1-2) - (1-21)), including other tautomers, stereoisomers, E / Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and also characterizes compositions, methods for treating or preventing pain ( eg, neuropathic pain), inflammation, or epilepsy and as anticonvulsants. Claim 1: A compound having the following structure (1a) and its tautomers (1b), including other tautomers, stereoisomers, E / Z stereoisomers, prodrugs and their pharmaceutically acceptable salts, wherein Q1 is -O-, -S-, - SO-, -SO2-, -CH2-, -CH2CH2-, -CH = CH-, -OCH2-, -SCH2-, -SOCH2-, or -SO2CH2-; V is O, S, NH, or NZ, or N-terminal linked amino acid, halogen, or H when R1 is absent; R1 is absent, -H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-12 cycloalkyl, C6-12 aryl, C7-14 arylalkyl, - (CH2) nOZ, -C (O) Z, -C (O) OZ, -C (O) NHZ, -C (O) N (Z) 2, - (CR1AR1B) r2OPO (OZ) 2, - (CR2AR2B) r3PO (OZ) 2, or C-linked amino acid -terminal; each R1A, R1B, R2A and R2B is, independently, H or C1-5 alkyl; each Z is, independently, -H, C1-8 alkyl, C4-12 alkylcycloalkyl, C3-9 alkylheterocyclyl, where the heterocyclyl is 3 to 9 members, C3-12 cycloalkyl, C6-12 aryl, C7-14 arylalkyl , 3 to 9 aromatic or non-aromatic heterocyclyl members, C2-8 alkenyl, or C2-8 alkynyl, or two Z, together with the atom (s) to which each is attached, join to form a 3 to 7 heterocycle aromatic or non-aromatic members; each n is 1 or 2; each R2 is an integer between 1-3; each r3 is an integer between 0-2; R2 and R3 are each, independently, -H, -D, -OH, -halogen, -CN, -NO2, -SH, -CF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-12 cycloalkyl, C6-12 aryl, C7-14 arylalkyl, 3- to 9-membered aromatic or non-aromatic heterocyclyl, -OZ, -N (Z) 2, -C (NH) N (Z) 2, -O ( CH2) nOZ, -C (O) Z, -OC (O) Z, -OC (O) OZ, -OC (O) N (Z) 2, -C (O) N (Z) 2, -C ( O) OZ, -SZ, -SOZ, -S (O) 2Z, -NHC (O) Z, -NHS (O) 2Z, -NHC (NH) N (Z) 2, -NZC (NH) N (Z ) 2, - NHC (NCN) N (Z) 2, -NZC (NCN) N (Z) 2, or -PO (OZ) 2, or R2 and R3, together with the atom to which each is attached, together to form an aromatic or non-aromatic 5 or 6-membered carbocycle or heterocycle; A1 and A2 are each, independently, -H, -D, -halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-12 cycloalkyl, C6-12 aryl, or C7 arylalkyl- 14; A3 is an aromatic heterocyclic ring selected from the group consisting of fragments A-1 to A-4; Q2, Q5 and Q6 are each, independently, N, N + -O-, or C; Q3 and Q4 are each, independently, N, N + -O-, C, O, or S, where only one of Q3 and Q4 can be O or S; where Q2, Q3, Q4, Q5 and Q6 simultaneously are C only if R4 and R5, R5 and R6, R6 and R7, or R7 and R8, together with the atoms to which each is attached, join to form a heterocyclyl of 5 to 6 aromatic or non-aromatic members; and R4, R5, R6, R7 and R8 are each, independently, absent, -H, -D, -OH, -O, -halogen, -CN, -NO2, -SH, C1-8 alkyl, alkenyl C2-8, C2-8 alkynyl, C3-12 cycloalkyl, C6-12 aryl, C7-14 arylalkyl, 3- to 9-membered aromatic or non-aromatic heterocyclyl, -OZ, -N (Z) 2, -C (NH) N (Z) 2, -O (CH2) nOZ, -C (O) Z, -OC (O) Z, -OC (O) OZ, -OC (O) N (Z) 2, -C (O) N (Z) 2, -C (O) OZ, -SZ, -SOZ, -S (O) 2Z, -NHC (O) Z, -NHS (O) 2Z, -NHC (NH) N (Z) 2 , -NZC (NH) N (Z) 2, -NHC (NCN) N (Z) 2, -NZC (NCN) N (Z) 2, -PO (OZ) 2, or R4 and R5, or R5 and R6 , or R6 and R7, or R7 and R8, together with the atoms to which each is attached, join to form an aromatic or non-aromatic 5 to 6-membered carbocycle or heterocycle as long as the resulting ring system is not substituted or unsubstituted benzimidazole, unsubstituted benzothiazole, unsubstituted imidazo [1,2-a] pyridine, 5- or 6- chloro-imidazo [1,2-a] pyridine, indole when R2 is C (O) OCH2CH3, unsubstituted quinoline , 8-substituted quinoline, unsubstituted quinoxaline, 2- or 4-chloro-quin oline, 2-chloro-7-methyl-quinoline or 2-piperidin-1-yl-quinoline when R3 is NH2, or 4-hydroxy-1,3-quinazoline, where when A3 is unsubstituted pyridine-2-yl and A1 , and A2 are each -H, R3 is not -H, -OH, -NH2, -CF3, C1-3 alkyl, phenyl, difluorobenzyl, -NHC (O) furan, -NHC (O) CH3, or -NHC (O) CH2CH3; where when A3 is unsubstituted pyridine-4-yl and A1 and A2 are each -H, R3 is not -H, -OH, -NH2, -CH3, -CH2CH2CH3, or difluorobenzyl; where when A3 is unsubstituted, 6-chloro, or 2,6-dichloro pyridine-3-yl and A1 and A2 are each -H, R3 is not -H, -OH, -NH2, -CF3, C1- alkyl 3, phenyl, -C (O) OCH2CH3, or -NHC (O) CH3; where when A3 is substituted or unsubstituted pyrazol-1-yl, R3 is not -OH; and where A3 is not 4-NO2-imidazol-2-yl. |
| priorityDate | 2009-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.